Literature DB >> 31957919

The disruption of invariant natural killer T cells exacerbates cardiac hypertrophy and failure caused by pressure overload in mice.

Masashige Takahashi1, Shintaro Kinugawa1, Shingo Takada1, Naoya Kakutani1, Takaaki Furihata1, Mochamad Ali Sobirin2, Arata Fukushima1, Yoshikuni Obata1, Akimichi Saito1, Naoki Ishimori1, Kazuya Iwabuchi3, Hiroyuki Tsutsui4.   

Abstract

NEW
FINDINGS: What is the central question of this study? We questioned whether the disruption of invariant natural killer T (iNKT) cells exacerbates left ventricular (LV) remodelling and heart failure after transverse aortic constriction in mice. What are the main findings and their importance? Pressure overload induced by transverse aortic constriction increased the infiltration of iNKT cells in mouse hearts. The disruption of iNKT cells exacerbated LV remodelling and hastened the transition from hypertrophy to heart failure, in association with the activation of mitogen-activated protein kinase signalling. Activation of iNKT cells modulated the immunological balance in this process and played a protective role against LV remodelling and failure. ABSTRACT: Chronic inflammation is involved in the development of cardiac remodelling and heart failure (HF). Invariant natural killer T (iNKT) cells, a subset of T lymphocytes, have been shown to produce various cytokines and orchestrate tissue inflammation. The pathophysiological role of iNKT cells in HF caused by pressure overload has not been studied. In the present study, we investigated whether the disruption of iNKT cells affected this process in mice. Transverse aortic constriction (TAC) and a sham operation were performed in male C57BL/6J wild-type (WT) and iNKT cell-deficient Jα18 knockout (KO) mice. The infiltration of iNKT cells was increased after TAC. The disruption of iNKT cells exacerbated left ventricular (LV) remodelling and hastened the transition to HF after TAC. Histological examinations also revealed that the disruption of iNKT cells induced greater myocyte hypertrophy and a greater increase in interstitial fibrosis after TAC. The expressions of interleukin-10 and tumour necrosis factor-α mRNA and their ratio in the LV after TAC were decreased in the KO compared with WT mice, which might indicate that the disruption of iNKT cells leads to an imbalance between T-helper type 1 and type 2 cytokines. The phosphorylation of extracellular signal-regulated kinase was significantly increased in the KO mice. The disruption of iNKT cells exacerbated the development of cardiac remodelling and HF after TAC. The activation of iNKT cells might play a protective role against HF caused by pressure overload. Targeting the activation of iNKT cells might thus be a promising candidate as a new therapeutic strategy for HF.
© 2020 The Authors. Experimental Physiology © 2020 The Physiological Society.

Entities:  

Keywords:  cardiac failure; cardiac hypertrophy; hypertrophy; inflammation; natural killer T cells

Year:  2020        PMID: 31957919     DOI: 10.1113/EP087652

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  4 in total

1.  The heart under pressure: immune cells in fibrotic remodeling.

Authors:  Brandon Theall; Pilar Alcaide
Journal:  Curr Opin Physiol       Date:  2022-01-22

2.  A New Minimally Invasive Method of Transverse Aortic Constriction in Mice.

Authors:  Huayang Li; Quan Liu; Shunjun Wang; Lin Huang; Suiqing Huang; Yuan Yue; Kangni Feng; Zhongkai Wu
Journal:  J Cardiovasc Transl Res       Date:  2021-09-08       Impact factor: 3.216

3.  Treatment of Left Ventricular Circulation Disorder: Application of Echocardiography Information Data Monitoring.

Authors:  Yulong Chen; Jianxia Du; Xiao Sun; Qiancheng Li; Ming Qin; Qian Xiao; Mark Bryan
Journal:  JMIR Med Inform       Date:  2020-09-16

Review 4.  A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair.

Authors:  Kang Sun; Yi-Yuan Li; Jin Jin
Journal:  Signal Transduct Target Ther       Date:  2021-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.